PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: Azoth Analytics (P) Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Azoth Analytics Releases Global NASH Non Alcoholics Steatohepatitis Market 2015-2030 Report - Global NASH (Non Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) (By Region, By Drugs Off Label & Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market)
Azoth Analytics Releases Global NASH Non Alcoholics Steatohepatitis Market 2015-2030 Report

 

NewswireToday - /newswire/ - Delhi, New Delhi, India, 2015/12/15 - Global NASH (Non Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) (By Region, By Drugs Off Label & Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Executive Summary

Progressive numbers of Liver disorders along with rise in obesity will fuel the demand for NASH Drugs

The Global NASH Market is growing at a moderate rate over last five years on account of rising number of obesity among young population. NASH (non-alcoholic steatohepatitis) is a large, un-tapped market with no FDA approved therapeutics. Antioxidants, anti-diabetic medications, anti-obesity medications and antihyper Lipidemics are some of the off-label products currently used by NASH patients. Moreover, increase in number of patients suffering from fat in liver disorder is further anticipated to boost the Global NASH market in the coming years.

According to Azoth Analytics research report,“Global NASH (Non Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) - (By Region, By Drugs Off Label & Special Treatment, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market)”, global non-alcoholic steatohepatitis drug specific market is estimated to start growing by 2020 at a CAGR of 25.56% during 2020-2030, due to the projected product launches in 2020. Surge in cycles of clinical trials and their success rate has improved the probability of industries receiving commercial approval for NASH therapeutics by the end of 2020. Additionally, the absence of efficient diagnostic technologies acts as a major hurdle for the research of NASH therapeutics.

Nevertheless, the emergence of novel biomarker technologies and improvements in liver biopsy technologies are expected to bring about an evolution in the diagnosis of NASH and other fatty liver diseases. Despite of these challenges, certain key players such as Galmed Pharmaceuticals, Gilead Sciences, Novo Nordisk, Genfit, Intercept and Galectin Therapeutics are conducting extensive research on NASH therapeutics and are receiving positive results from clinical trials. But, the low diagnosis rates, low prescription rates and low treatment seeking rates continue to pose significant challenges for these emerging players. The United States, which has the highest number of research initiatives concerning NASH, holds nearly half of the global market share. The chief reason behind this growth is the high prevalence of diabetes and obesity and the growing number of people suffering with these conditions. The US has the highest number cases of NASH and other non-alcoholic fatty liver diseases.

Scope of the Report

Global NASH (Non Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) - (By Region, By Drugs Off Label & Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market) analyses the following aspects of global Alzheimer’s market:

- Global NASH Market Size, Share & Forecast
- Segmental Analysis By off Label, By Specific Drug and By Patient
- Policy & Regulatory Landscape
- Changing Market Trends & Emerging Opportunities
- Competitive Landscape & Strategic Recommendations

List of Figures

1. Global NAFLD Population; 2015-2035E (In Million)
2. Global NASH Population; 2015-2035E (In Million)
3. Global Prevalence of NASH, 2014 In Percentage
4. Global NASH (Pre- fibroctic and early- stage fibrosis) Diagnosed Cases ; 2015-2035E (In Million)
5. Global NASH Off Label Drug Market by Value ; USD Million In (2012-2019E)
6. Global NASH Off Label Drug Market by Region ; USD Million In (2012-2019E)
7. Global GFT 505 Market by Value: 2017E-2030E (USD Billion)
8. GFT 505 Estimated Valuation: In USD Million
9. GFT505 Market by Value: 2020E- 2030E (USD Million)
10. Aramchol Market by Value: 2021E- 2035E (USD Million)
11. Aramchol Market by Volume: 2021E- 2035E (in Thousand)
12. GR-MD-02 Market by Value; 2021E-2030E (US$ Million)
13. The US NAFLD Population; 2015-2035E (In Million)
14. The US NASH Population; 2015-2035E (In Million)
15. Diagnose Rate of NASH in the US; 2021E-2028E (In %)
16. Treatment Rate of NASH in the US; 2021E- 2028E IN Percentage
17. The US NASH of Label Drug Market By Value; 2012-2017E (USD Million)
18. The US NASH Market By Value; 2019-2030E (USD Billion)
19. Aramchol Sales in the US; 2021E- 2035E (USD Million)
20. Number of Patient Receiving Aramchol Treatment in the US: 2021E- 2035E In Thousands
21. Aramchol Penetration Rate in US; 2021E 2035E
22. Aramchol Cost of Treatment in US; 2021E- 2035E In Thousands
23. GFT 505 Net Sales in the North America : 2020E- 2030E (USD Million)
24. GR-MD-02 Sales in US: 2021E-2033E (USD Billion)
25. Number of Patient Receiving GR-MD-02 Treatment in US: 2021E-2033E In Thousand
26. GR-MD-02 Annual Cost of Treatment in the US: 2021E-2035E In Thousands
27. Europe NAFLD Population: 2015-2035E In Million
28. Europe NASH Population: 2015-2035E (In Million)
29. Europe NASH Pre- Firoctics & Early Fibrosis Cases: 2015-2035E In Million
30. Europe NASH Prevalence Rate In Percentage 2021E-2028E
31. Europe NASH Diagnosed Cases: 2015-2035E In Million
32. Europe Diagnosis Rate 2021E-2028E
33. Europe Treatment Rate of NASH in Europe: 2021E-2028E In Percentage
34. Europe NASH Market by Value: 2012-2019E USD Million
35. Europe Treatment Rate of NASH in Europe: 2021E-2028E In Percentage
36. Europe NASH Market By Value: 2021E-2030E USD Billion
37. Europe NASH Market by Value: 2012-2019E USD Million
38. Europe NASH Market By Value: 2021E-2030E USD Billion
39. Europe Aramchol Penetration Rate in Europe: 2021E-2035E In Percentage
40. Europe Aramchol Annual Cost Of Treatment in Europe : 2021E-2035E In Thousands
41. Europe NASH Market By Value: 2021E-2030E USD Billion
42. Japan NASH Therapeutics Market by Value: 2023E- 2030E USD Billion
43. Galmed Pharmaceuticals Share Price 25th November 2015- 25 November 2014.

About Azoth Analytics (P) Ltd

Our business research and market analysis (azothanalytics.com) helps organizations across different industry verticals solve their business problems. We are always scrupulous about our work and provide customized market research reports revealing the hidden truths on different verticals like pharmaceutical, oil and gas, telecommunications, real estate, logistics, energy, healthcare, technology, FMCG, food & beverages and media sectors.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Azoth Analytics (P) Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Azoth Analytics Releases Global NASH Non Alcoholics Steatohepatitis Market 2015-2030 Report

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Subhodeep Sen - AzothAnalytics.com 
+91 98 11715635 info[.]azothanalytics.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Azoth Analytics (P) Ltd securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Azoth Analytics (P) Ltd / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
The Float Space - Brisbane's First Float and Cryo Therapy Centre to Open This November
Thought Leaders Across the Healthcare Spectrum to Participate in Industry-Wide Survey
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Moriarty Physical Therapy of the Hudson Valley Expands with New Office in Lagrange, NY
Ultimate Medical Group Announces A New Regenerative Medicine Division
Dr. Amir Hanna Introduces New Medical Innovation Taking the Pain Out of Physical Therapy
Samitivej Children’s Hospital Transforms its Sukhumvit Campus

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)